Lb Pharmaceuticals Common Stock Performance
| LBRX Stock | 23.82 0.04 0.17% |
On a scale of 0 to 100, LB Pharmaceuticals holds a performance score of 14. The firm owns a Beta (Systematic Risk) of -0.94, which conveys possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning LB Pharmaceuticals are expected to decrease slowly. On the other hand, during market turmoil, LB Pharmaceuticals is expected to outperform it slightly. Please check LB Pharmaceuticals' jensen alpha, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether LB Pharmaceuticals' current price history will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in LB Pharmaceuticals Common are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, LB Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 12.71 | Five Day Return 13.56 | Year To Date Return 16.73 | Ten Year Return 37.92 | All Time Return 37.92 |
1 | LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 | 11/12/2025 |
2 | LB Pharmaceuticals amends lease to expand New York office space - Investing.com | 11/13/2025 |
3 | LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices | 12/09/2025 |
4 | Medline sets terms for 5.37bn healthcare IPO - BioXconomy | 12/12/2025 |
5 | LB Pharmaceuticals Trading Down 5.5 percent Whats Next | 01/16/2026 |
6 | LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program | 01/26/2026 |
7 | LB Pharmaceuticals Announces 100.0 Million Private Placement | 02/05/2026 |
| Begin Period Cash Flow | 15 M | |
| Total Cashflows From Investing Activities | 23.2 M | |
| Free Cash Flow | -53.8 M |
LB Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,461 in LB Pharmaceuticals Common on November 8, 2025 and sell it today you would earn a total of 925.00 from holding LB Pharmaceuticals Common or generate 63.31% return on investment over 90 days. LB Pharmaceuticals Common is currently generating 0.9615% in daily expected returns and assumes 5.4259% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than LBRX, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
LB Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of LBRX Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 23.82 | 90 days | 23.82 | nearly 4.97 |
Based on a normal probability distribution, the odds of LB Pharmaceuticals to move above the current price in 90 days from now is nearly 4.97 (This LB Pharmaceuticals Common probability density function shows the probability of LBRX Stock to fall within a particular range of prices over 90 days) .
LB Pharmaceuticals Price Density |
| Price |
Predictive Modules for LB Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as LB Pharmaceuticals Common. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.LB Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. LB Pharmaceuticals is not an exception. The market had few large corrections towards the LB Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold LB Pharmaceuticals Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of LB Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.75 | |
β | Beta against Dow Jones | -0.94 | |
σ | Overall volatility | 2.67 | |
Ir | Information ratio | 0.13 |
LB Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of LB Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for LB Pharmaceuticals Common can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| LB Pharmaceuticals is way too risky over 90 days horizon | |
| LB Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| LB Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (63.1 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| LB Pharmaceuticals generates negative cash flow from operations | |
| LB Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: LB Pharmaceuticals Announces 100.0 Million Private Placement |
LB Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of LBRX Stock often depends not only on the future outlook of the current and potential LB Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. LB Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3.5 M | |
| Cash And Short Term Investments | 28 M |
LB Pharmaceuticals Fundamentals Growth
LBRX Stock prices reflect investors' perceptions of the future prospects and financial health of LB Pharmaceuticals, and LB Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on LBRX Stock performance.
| EBITDA | (63.01 M) | ||||
| Net Income | (63.1 M) | ||||
| Total Debt | 3.7 M | ||||
| Cash Flow From Operations | (53.05 M) | ||||
| Total Asset | 33.53 M | ||||
| Retained Earnings | (104.32 M) | ||||
| Working Capital | 20.77 M | ||||
About LB Pharmaceuticals Performance
Evaluating LB Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if LB Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if LB Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.16) | (2.06) | |
| Return On Capital Employed | (2.93) | (2.79) | |
| Return On Assets | (2.16) | (2.06) | |
| Return On Equity | 0.60 | 0.36 |
Things to note about LB Pharmaceuticals Common performance evaluation
Checking the ongoing alerts about LB Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for LB Pharmaceuticals Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| LB Pharmaceuticals is way too risky over 90 days horizon | |
| LB Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| LB Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (63.1 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| LB Pharmaceuticals generates negative cash flow from operations | |
| LB Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: LB Pharmaceuticals Announces 100.0 Million Private Placement |
- Analyzing LB Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether LB Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining LB Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating LB Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of LB Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of LB Pharmaceuticals' stock. These opinions can provide insight into LB Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for LBRX Stock Analysis
When running LB Pharmaceuticals' price analysis, check to measure LB Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LB Pharmaceuticals is operating at the current time. Most of LB Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of LB Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LB Pharmaceuticals' price. Additionally, you may evaluate how the addition of LB Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.